The billionaire industrialist noted that for getting into vaccine production, a completely new set of manufacturing infrastructure is required.
So, that's broadly our understanding. So, we currently don't have any facility which we are looking at for producing vaccines, Shanghvi said.
On the biosimilar front, he noted that the drug firm is looking to develop a range of such products.
We are evaluating development of some biosimilars which can be classified amongst the third wave of biosimilars, Shanghvi said while clarifying that the company is looking at 2030 kind of timeline for such products to hit the market.
A biosimilar is a product which is similar to another already approved biological medicine.
The company is looking at products which have significant future patent expiry dates so that it could be amongst the first firms to get initial approvals, Shanghvi said.
That's the focus and priority. And that's not the only (thing), there are multiple priorities, and also (we are) trying to find a way by which we can leverage our presence in the market so that we can successfully build a biosimilars portfolio, he added.
He noted that the development of the biosimilars would not be a 'big drain' on the company's cash flow and profitability.
Commenting on the US business, he said the drug firm's current generic pipeline for the US market includes 94 abbreviated new drug applications (ANDAs) and nine new drug applications (NDAs) awaiting approval with the US FDA.
In 2020-21, the company launched around 18 new products in the US.
On business outlook, Shanghvi noted: Given the uncertainties of the pandemic in the near term, we are refraining from giving guidance for FY22. However, all our businesses are well positioned and our endeavour will be to grow the business, notwithstanding the near term uncertainties related to COVID-19.
The drug firm's revenue from operations stood at Rs 33,498 crore in 2020-21.
Commenting on the company's Halol plant, which has been under the USFDA radar for the last few years, Shanghvi said the drug firm is waiting for the regulator to inspect the facility.
We have requested for an inspection. Now, I think it's up to them to inspect the facility. And hopefully this time we should be able to clear it successfully, that's the focus, he added.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.